TransAct Technologies Incorporated — FY 2013 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2013; it is an annual report, not a standalone fourth-quarter filing. TransAct designs and sells transaction printers, terminals, software, supplies and services across food safety/POS, casino and gaming, lottery, Printrex and TSG. It reports one operating segment.
Financial performance and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Net sales | $60.1 million | $68.4 million |
| Gross profit / gross margin | $25.1 million / 41.7% | $26.0 million / 38.0% |
| Operating income / operating margin | $6.6 million / 11.0% | $5.6 million / 8.2% |
| Net income / diluted EPS | $4.9 million / $0.57 | $3.6 million / $0.40 |
| Cash from operating activities | $2.5 million | $8.0 million |
- Fourth-quarter 2013 sales were $12.5 million, gross profit $5.0 million and net income $1.1 million, versus $19.6 million, $7.7 million and $1.9 million, respectively, in Q4 2012. Diluted EPS was $0.13 versus $0.21.
- At year-end, cash and cash equivalents were $2.9 million, working capital $24.9 million and the current ratio 4.4. Total assets were $40.4 million and shareholders’ equity $32.5 million.
- No debt was outstanding. The company had a $20 million revolving credit facility, fully undrawn at year-end, expiring November 28, 2014; management expected to renew or replace it during 2014. The company reported compliance with its financial covenants.
- Cash fell $4.6 million during 2013, primarily as the company repurchased $5.2 million of shares and paid $2.3 million in dividends. Capital expenditures were $0.7 million; 2014 capital expenditures were expected to be about $1.0 million.
Material changes versus prior periods
- Annual sales declined 12.1%; printer and terminal shipment volume fell 23% to about 153,000 units, while average selling price rose 7%.
- Lottery sales fell 61.8% to $4.5 million, largely because a large 2012 GTECH purchase of a discontinued printer did not recur. Casino and gaming sales declined 6.3%; Printrex fell 7.2% and TSG fell 5.2%.
- Food safety, banking and POS revenue increased 19.1% to $11.3 million, supported by the Ithaca 9700 food safety terminal. EPICENTRAL installations also contributed to domestic casino software growth.
- Gross margin reached a reported record 41.7%, up 370 basis points, reflecting a more favorable mix of value-added products and cost controls. Operating income rose 18.1%.
- Operating cash flow declined from $8.0 million to $2.5 million, with inventory increasing $3.2 million as the company stocked new food-safety and Printrex products. Management expected inventory to decline gradually in 2014.
Outlook, risks and unusual items
- Management expected further 2014 growth in Ithaca 9700 and EPICENTRAL sales, gradual growth in Printrex color printers, and continued improvement in gross margin. It expected 2014 engineering and selling/marketing expenses to increase, G&A to be broadly consistent excluding the 2013 contingent-consideration credit, and the effective tax rate to be 32%–33%.
- Management forecast 2014 GTECH sales of approximately $4–$5 million, TSG sales below 2013 levels, and about $2.4 million of cash dividends. These are company expectations, not guarantees.
- GTECH and another customer each represented 12% of 2013 sales. The GTECH thermal lottery printer agreement was exclusive through November 2014, creating customer concentration and renewal/timing risk. Backlog was about $4.8 million at February 28, 2014, with shipments expected during 2014.
- Approximately 90% of printer production was handled by one Asian contract manufacturer. Key sole-source exposures include HP inkjet cartridges, ZINK color thermal paper for Printrex 920, and Canon consumables for Printrex 980.
- Avery Dennison alleged trade-secret misappropriation and sought to block sales of the Ithaca 9700 and 9800. Courts denied the requested injunction, and the appellate court affirmed in TransAct’s favor in October 2013; Avery Dennison sought reconsideration. TransAct incurred $0.5 million in related legal fees in 2013 and said further fees were possible.
- A $0.9 million reduction in the Printrex contingent-consideration estimate was credited to 2013 G&A, boosting reported operating income. The 2013 effective tax rate of 24.4% was unusually low, including a $0.224 million reduction in unrecognized tax benefits and an approximately $0.220 million R&D-credit benefit.
- Other risks include market acceptance and integration timing for new products, competitive pricing, international exposure, inventory forecasting, and patent or intellectual-property disputes. Management and PwC reported effective disclosure controls and internal control over financial reporting at year-end.
Important facts for investors to verify
- Whether food-safety and EPICENTRAL sales convert trials, installations and positive customer feedback into sustained revenue and margins.
- GTECH agreement status and order timing after the disclosed exclusivity period, as well as the durability of revenue from major customers.
- Inventory sell-through, operating cash-flow recovery and the effect of lower sales volume on working capital.
- Renewal or replacement of the revolving credit facility before its November 2014 expiration.
- Developments in the Avery Dennison litigation and any resulting legal expense or constraints on food-safety products.
- Whether the 2013 margin and earnings improvement persists after the one-time contingent-consideration credit and unusually low tax rate.